Skip to content
Hair Pipeline
enfr
← Recruiting trials
NCT04784533Phase 2Completed

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

In the register

The register attaches this trial to Deuruxolitinib (Leqselvi) (Sun Pharmaceutical), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status
Completed
Declared phase
Phase 2
Sponsor
Concert Pharmaceuticals
Participants (registry)
317
Start
February 2021
Primary completion
May 2023
Study completion
May 2023
Last registry update
October 2024
Countries
United States

Conditions studied: Alopecia Areata

Interventions: CTP-543, Placebo

Full record on ClinicalTrials.gov ↗

Other trials of Deuruxolitinib (Leqselvi)

  • NCT07617597Phase 3Recruiting

    Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

  • NCT07133308Phase 3Recruiting

    Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

  • NCT05041803Phase 3Completed

    European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  • NCT04797650Phase 3Completed

    Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

  • NCT04518995Phase 3Completed

    Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

  • NCT03941548Phase 2Completed

    Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

  • NCT03898479Phase 2/3Active, not recruiting

    Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  • NCT03811912Phase 2Completed

    Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

  • NCT03137381Phase 2Completed

    Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.